A Phase 1 interventional study of Budesonide in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-02.
Sponsored by Takeda · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main aim of this study is to check what the body of a healthy adult who either fasted or had eaten does to TAK-721 and how TAK-721 is distributed in and removed from the body. Other aims are to learn how safe the treatment with TAK-721 is and how suitable the TAK-721 is for healthy adults who either fasted or had eaten. All participants will receive TAK-721 but half will be assigned by chance to the participant group who are fasting first then getting the high-fat/high-calorie meal later or the group who gets meal first and fasts later. The group assignment will be switched once during the course of the study so that all participants will receive TAK-721 in both a fasted or fed condition.
The drug being tested in this study is called budesonide. Budesonide oral suspension (BOS) is being tested in healthy adult participants. This study will determine whether the absorption of BOS will be altered if taken with food.
The study will enroll approximately 20 patients. The study will consist of two treatment sequences and two periods separated by a washout period of 2 days. Participants will be randomly assigned (by chance, like flipping a fair coin) to one of the two treatment sequences:
This single center trial will be conducted in the United States. Participation in the study is up to approximately 34 days. Participants will visit the clinic approximately three days after last dose of study drug for a follow-up assessment.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participant is unable to refrain from or anticipates the use of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 2 mg BOS, single dose, orally on Day 1 of Period 1 under fasted condition (Treatment A). Two days later, participants will receive 2 mg BOS single dose, orally on Day 1 of Period 2 under fed condition (Treatment B).
Drug: Budesonide
Participants will receive 2 mg BOS, single dose, orally on Day 1 of Period 1 under fed condition (Treatment B). Two days later, participants will receive 2 mg BOS single dose, orally on Day 1 of Period 2 under fasted condition (Treatment A).
Drug: Budesonide
Budesonide oral suspension
Also known as: TAK-721
Maximum Observed Concentration (Cmax) of BOS
Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of BOS
Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Area Under the Concentration-time Curve From Time 0 to Infinity (AUC∞) of BOS
Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE), Serious Adverse Events (SAE), and Death
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. An SAE was defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that may require an intervention to prevent above items and expose the participant to danger.
Time frame: From first dose of study drug up to the end of study (EOS) (Up to 15 days)
Number of Participants With Clinically Significant Abnormal Vital Sign Values Reported as Adverse Events
Vital signs included body temperature, respiratory rate, blood pressure, and pulse rate evaluations.
Time frame: From first dose of study drug up to EOS (Up to 15 days)
Number of Participants With Clinically Significant Abnormal Clinical Laboratory Values Reported as Adverse Events
Clinical laboratory parameters included hematology, clinical chemistry, serum immunoglobulin and urinalysis tests.
Time frame: From first dose of study drug up to EOS (Up to 15 days)
Area Under the Concentration-time Curve From Time 0 to 12 Hours (AUC0-12) of BOS
Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 12 hours) post-dose on Day 1
Area Under the Curve From the Last Quantifiable Concentration to Infinity Expressed as a Percentage of AUC∞ (AUCextrap%) of BOS
Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Time to First Occurrence of Cmax (Tmax) of BOS
Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Lag Time to First Quantifiable Concentration (Tlag) of BOS
Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Terminal Disposition Phase Half-life (t1/2z) of BOS
Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Terminal Disposition Phase Rate Constant (λz) of BOS
Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Apparent Clearance (CL/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS
Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Apparent Volume of Distribution During the Terminal Disposition Phase (Vz/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS
Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Participants took part in the study at 1 investigative site in the United States from 6 February 2023 to 20 February 2023.
| Milestone | Sequence 1: BOS 2 mg Fasted, Then Fed | Sequence 2: BOS 2 mg Fed, Then Fasted |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
| Milestone | Sequence 1: BOS 2 mg Fasted, Then Fed | Sequence 2: BOS 2 mg Fed, Then Fasted |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
| picograms per milliliter (pg/mL) | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Maximum Observed Concentration (Cmax) of BOS | 692.9 ± 54.4 | 604.1 ± 46.6 |
| picograms*hours per milliliter (pg*h/mL) | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of BOS | 2811 ± 57.5 | 3529 ± 52.1 |
| pg*h/mL | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Area Under the Concentration-time Curve From Time 0 to Infinity (AUC∞) of BOS | 3075 ± 57.0 | 3892 ± 47.1 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. An SAE was defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that may require an intervention to prevent above items and expose the participant to danger.
| Participants | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| TEAEs | 2 | 5 |
| SAEs | 0 | 0 |
| Deaths | 0 | 0 |
Vital signs included body temperature, respiratory rate, blood pressure, and pulse rate evaluations.
| Participants | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Number of Participants With Clinically Significant Abnormal Vital Sign Values Reported as Adverse Events | 0 | 0 |
Clinical laboratory parameters included hematology, clinical chemistry, serum immunoglobulin and urinalysis tests.
| Participants | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Number of Participants With Clinically Significant Abnormal Clinical Laboratory Values Reported as Adverse Events | 0 | 0 |
| pg*h/mL | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Area Under the Concentration-time Curve From Time 0 to 12 Hours (AUC0-12) of BOS | 2728 ± 53.0 | 3208 ± 42.2 |
| percentage of AUC | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Area Under the Curve From the Last Quantifiable Concentration to Infinity Expressed as a Percentage of AUC∞ (AUCextrap%) of BOS | 7.275 ± 61.7 | 7.126 ± 75.6 |
| hours (h) | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Time to First Occurrence of Cmax (Tmax) of BOS | 1.286 (0.55 to 2.57) | 2.516 (1.01 to 6.03) |
| hours | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Lag Time to First Quantifiable Concentration (Tlag) of BOS | 0.328 (0.26 to 0.56) | 0.308 (0.25 to 0.53) |
| hours | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Terminal Disposition Phase Half-life (t1/2z) of BOS | 4.270 (2.13 to 6.98) | 5.096 (2.78 to 7.35) |
| 1/hour | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Terminal Disposition Phase Rate Constant (λz) of BOS | 0.1627 (0.0994 to 0.325) | 0.1362 (0.0943 to 0.249) |
| liters per hour (L/h) | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Apparent Clearance (CL/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS | 650.4 ± 57.0 | 513.9 ± 47.1 |
| liters (L) | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Apparent Volume of Distribution During the Terminal Disposition Phase (Vz/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS | 3967 ± 45.0 | 3513 ± 32.9 |
Collected over From first dose of study drug up to the EOS (15 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: BOS 2 mg Fasted | 0/20 (0%) | 0/20 (0%) | 2/20 (10%) |
| Treatment B: BOS 2 mg Fed | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| Event | Treatment A: BOS 2 mg Fasted | Treatment B: BOS 2 mg Fed |
|---|---|---|
| Vessel puncture site painGeneral disorders | 0/20 | 2/20 |
| HeadacheNervous system disorders | 2/20 | 1/20 |
| DiarrhoeaGastrointestinal disorders | 0/20 | 1/20 |
| Vessel puncture site bruiseGeneral disorders | 0/20 | 1/20 |
| Vessel puncture site swellingGeneral disorders | 0/20 | 1/20 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/20 | 0/20 |
Safety Set included all participants who received any study drug.
| Age, Continuous(years) | Sequence 1: BOS 2 mg Fasted, Then Fed | Sequence 2: BOS 2 mg Fed, Then Fasted | Total |
|---|---|---|---|
| Mean | 38.6 ± 9.50 | 32.7 ± 9.97 | 35.7 ± 9.95 |
| Sex: Female, Male(Participants) | Sequence 1: BOS 2 mg Fasted, Then Fed | Sequence 2: BOS 2 mg Fed, Then Fasted | Total |
|---|---|---|---|
| Female | 7 | 5 | 12 |
| Male | 3 | 5 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Sequence 1: BOS 2 mg Fasted, Then Fed | Sequence 2: BOS 2 mg Fed, Then Fasted | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 8 | 9 | 17 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sequence 1: BOS 2 mg Fasted, Then Fed | Sequence 2: BOS 2 mg Fed, Then Fasted | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 5 | 6 | 11 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body Mass Index (BMI)(kilograms per metre square (kg/m^2)) | Sequence 1: BOS 2 mg Fasted, Then Fed | Sequence 2: BOS 2 mg Fed, Then Fasted | Total |
|---|---|---|---|
| Mean | 27.52 ± 2.910 | 27.59 ± 2.706 | 27.56 ± 2.735 |
| Height(centimetres (cm)) | Sequence 1: BOS 2 mg Fasted, Then Fed | Sequence 2: BOS 2 mg Fed, Then Fasted | Total |
|---|---|---|---|
| Mean | 165.4 ± 10.71 | 169.0 ± 11.52 | 167.2 ± 10.98 |
| Weight(kilograms (kg)) | Sequence 1: BOS 2 mg Fasted, Then Fed | Sequence 2: BOS 2 mg Fed, Then Fasted | Total |
|---|---|---|---|
| Mean | 75.99 ± 15.39 | 79.51 ± 14.53 | 77.75 ± 14.68 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Feb 2023 to primary completion in Feb 2023, 0 months.
Results were first posted in Dec 2024, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide